Literature DB >> 10588056

The AgNORs.

M Derenzini1.   

Abstract

The structure and the function of interphase AgNORs and the importance of the "AgNOR" parameter in tumor pathology have been reviewed. Interphase AgNORs are structural-functional units of the nucleolus in which all the components necessary for ribosomal RNA synthesis are located. Two argyrophilic proteins involved in rRNA transcription and processing, nucleolin and nucleophosmin, are associated with interphase AgNORs and are responsible for their stainability with silver methods, thus allowing interphase AgNORs to be visulaized at light microscopic level, also in routine cyto-histopathological preparations. The number of interphase AgNORs is strictly related to rRNA transcriptional activity and, in continuously proliferating cells, to the rapidity of cell proliferation. Evaluation of the quantitative distribution of interphase AgNORs has been applied in tumor pathology both for diagnostic and prognostic purposes. The "AgNOR" parameter has been proved to represent a reliable tool for defining the clinical outcome of cancer disease, being an independent prognostic factor in many types of tumors.

Entities:  

Mesh:

Year:  2000        PMID: 10588056     DOI: 10.1016/s0968-4328(99)00067-0

Source DB:  PubMed          Journal:  Micron        ISSN: 0968-4328            Impact factor:   2.251


  52 in total

Review 1.  Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer.

Authors:  Paula J Bates; Damian A Laber; Donald M Miller; Shelia D Thomas; John O Trent
Journal:  Exp Mol Pathol       Date:  2009-01-20       Impact factor: 3.362

2.  Nucleolar organizer regions in a chronic stress and oral cancer model.

Authors:  Ivonne Andrea Muñoz Ruz; Daniel Andrés Droguett Ossa; Wendy Karina Donoso Torres; Ulrike Kemmerling; Bernardo Arturo Venegas Rojas; César Andrés Rivera Martínez
Journal:  Oncol Lett       Date:  2011-12-06       Impact factor: 2.967

3.  To the intranucleolar translocation of AgNORs in leukemic early granulocytic and plasmacytic precursors.

Authors:  Karel Smetana; Hana Klamová; Michaela Pluskalová; Petr Stöckbauer; Zbynek Hrkal
Journal:  Histochem Cell Biol       Date:  2005-09-02       Impact factor: 4.304

4.  Nucleophosmin sets a threshold for p53 response to UV radiation.

Authors:  Dony A Maiguel; Leslie Jones; Devulapalli Chakravarty; Chonglin Yang; France Carrier
Journal:  Mol Cell Biol       Date:  2004-05       Impact factor: 4.272

5.  Relationships between transcription, silver staining, and chromatin organization of nucleolar organizers in Secale cereale.

Authors:  Ana D Caperta; Nuno Neves; Wanda Viegas; Craig S Pikaard; Sasha Preuss
Journal:  Protoplasma       Date:  2007-12-24       Impact factor: 3.356

6.  Inhibition of migration but stimulation of proliferation of human retinal pigment epithelial cells cultured with uniform vesicles of silicone oil.

Authors:  Li-Na Ma; Yan-Nian Hui; Yu-Sheng Wang; Le Zhang; Ji-Xian Ma
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-11-27       Impact factor: 3.117

Review 7.  Nucleolus, ribosomes, and cancer.

Authors:  Lorenzo Montanaro; Davide Treré; Massimo Derenzini
Journal:  Am J Pathol       Date:  2008-06-26       Impact factor: 4.307

8.  Multifactorial analysis of predictors of outcome in pediatric intracranial ependymoma.

Authors:  Lee Ridley; Ruman Rahman; Marie-Anne Brundler; David Ellison; James Lowe; Keith Robson; Emma Prebble; Inga Luckett; Richard J Gilbertson; Sheila Parkes; Vikki Rand; Beth Coyle; Richard G Grundy
Journal:  Neuro Oncol       Date:  2008-08-13       Impact factor: 12.300

9.  Dysregulation of ribosome biogenesis and translational capacity is associated with tumor progression of human breast cancer cells.

Authors:  Stéphane Belin; Anne Beghin; Eduardo Solano-Gonzàlez; Laurent Bezin; Stéphanie Brunet-Manquat; Julien Textoris; Anne-Catherine Prats; Hichem C Mertani; Charles Dumontet; Jean-Jacques Diaz
Journal:  PLoS One       Date:  2009-09-25       Impact factor: 3.240

10.  Nucleic acid aptamers for targeting of shRNA-based cancer therapeutics.

Authors:  John S Vorhies; John J Nemunaitis
Journal:  Biologics       Date:  2007-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.